Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

Summit Raises $200 Million; Also Expands License Territories for Ivonescimab

Source: 
BioSpace
snippet: 
  • $200 Million in Net Proceeds Raised at Premium to Previous Closing Price
  • In Separate Transaction, Summit Expanded License Territories for Ivonescimab in Deal with Akeso to include Latin America, Middle East, and Africa
  • Expansion Is in Addition to Existing License Territories of US, Canada, Europe, and Japan